{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:56:00Z","timestamp":1781337360481,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jcyt.2025.102002","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:58:27Z","timestamp":1763186307000},"page":"102002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-6221","authenticated-orcid":false,"given":"Soo Jung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngwoo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Won","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-5501","authenticated-orcid":false,"given":"Dong Wook","family":"Jekarl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-0287","authenticated-orcid":false,"given":"Jae Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-390X","authenticated-orcid":false,"given":"Nack-Gyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9131","authenticated-orcid":false,"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.102002_bib0001","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.3390\/cancers13194789","article-title":"Real world evidence of CAR T-cell therapies for the treatment of relapsed\/refractory B-cell non-Hodgkin lymphoma: a monocentric experience","volume":"13","author":"Casadei","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jcyt.2025.102002_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1032664","article-title":"Efficacy and safety of blinatumomab in children with relapsed\/refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcyt.2025.102002_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231154713","article-title":"Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score\u2013matched cohort analysis","volume":"14","author":"Yoon","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jcyt.2025.102002_bib0004","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1002\/cam4.2680","article-title":"Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"8","author":"Yoon","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jcyt.2025.102002_bib0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2025.102002_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102002_bib0007","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102002_bib0008","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102002_bib0009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36401\/JIPO-21-2","article-title":"Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?","volume":"4","author":"Tang","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.jcyt.2025.102002_bib0010","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102002_bib0011","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1097\/HS9.0000000000000817","article-title":"Outcome prediction in patients with large B-cell lymphoma undergoing chimeric antigen receptor T-cell therapy","volume":"7","author":"Voltin","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jcyt.2025.102002_bib0012","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2023.066","article-title":"CAR-T cell therapy in large B cell lymphoma","volume":"15","author":"Testa","year":"2023","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jcyt.2025.102002_bib0013","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102002_bib0014","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102002_bib0015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2025.102002_bib0016","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/trf.14569","article-title":"Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma","volume":"58","author":"Ceppi","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2025.102002_bib0017","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/cells9051225","article-title":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed\/refractory NHL or ALL","volume":"9","author":"Korell","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.jcyt.2025.102002_bib0018","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.102002_bib0019","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.102002_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.06.007","article-title":"Leukapheresis and tisagenlecleucel manufacturing outcomes in patients age <3 years with relapsed\/refractory acute lymphoblastic leukemia","volume":"29","author":"Fong","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.102002_bib0021","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102002_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102002_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23589-9","article-title":"T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy","volume":"12","author":"Wada","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2025.102002_bib0024","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/bloodadvances.2024012563","article-title":"Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma","volume":"8","author":"Carniti","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102002_bib0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.102002_bib0026","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102002_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-143336","article-title":"Factors affecting lymphocyte collection efficiency and manufactured product specification during leukapheresis for diffuse large B cell lymphoma patients treated with commercial tisagenlecleucel","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102002_bib0028","first-page":"221","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","author":"Ayala","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2025.102002_bib0029","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102002_bib0030","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2022008240","article-title":"Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL","volume":"7","author":"Zurko","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102002_bib0031","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers15061747","article-title":"Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed\/refractory large B cell lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jcyt.2025.102002_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e19568","article-title":"Association of PET\/CT response assessment prior to CAR T-cell infusion with outcomes after CAR T-cell therapy in aggressive B-cell lymphomas","volume":"39","author":"Nader","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102002_bib0033","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/blood.2020009515","article-title":"Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy","volume":"138","author":"Wudhikarn","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102002_bib0034","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.102002_bib0035","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102002_bib0036","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients\u2014a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2025.102002_bib0037","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:15:15Z","timestamp":1781334915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925008977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1465324925008977"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102002"}}